CIK 0001211583 · Non-accelerated filer<br>Smaller reporting company
FENNEC PHARMACEUTICALS INC.
Sign in to watch- Ticker
- FENC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- (919) 636-4530
- Business address
- PO BOX 13628, 68 TW ALEXANDER DRIVE, RESEARCH TRIANGLE PARK, NC, 27709
- Former names
- ADHEREX TECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,310,718
- in 4 filings, $1.2M under 10b5-1 plans
Net −$1,310,718. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-03 | Brughera Marco Maria Director | Grant or award · Stock Option | +20,000 | $7.88 | $158K | 215,545 |
| 2025-06-03 | RALLIS CHRIS A Director | Grant or award · Stock Option | +20,000 | $7.88 | $158K | 200,533 |
| 2025-06-03 | Islam Khalid Director | Grant or award · Stock Option | +25,000 | $7.88 | $197K | 225,000 |
| 2025-05-31 | Raykov Rosty Director | Grant or award | +5,208 | 75,462 | ||
| 2025-05-31 | Andrade Robert CHIEF FINANCIAL OFFICER | Grant or award | +2,431 | 160,951 | ||
| 2025-05-22 | Andrade Robert CHIEF FINANCIAL OFFICER | Option exercise | +8,220 | $5.10 | $42K | 158,520 |
| 2025-05-22 | Andrade Robert CHIEF FINANCIAL OFFICER | Option exercise · Stock Options | −8,220 | $5.10 | $42K | 850,751 |
| 2025-05-19 | Hackman Jeffrey S. Chief Executive Officer | Purchase | +13,965 | $6.99 | $98K | 15,000 |
| 2025-05-16 | Hackman Jeffrey S. Chief Executive Officer | Purchase | +1,035 | $6.75 | $7K | 1,035 |
| 2025-05-16 | Raykov Rosty Director | Grant or award | +33,334 | 86,921 | ||
| 2025-05-16 | Raykov Rosty Director | Sale | −16,667 | $6.78 | $113K | 70,254 |
| 2025-05-16 | Andrade Robert CHIEF FINANCIAL OFFICER | Grant or award | +16,667 | 150,300 | ||
| 2025-05-05 | Raykov Rosty Director | Sale 10b5-1 | −10,000 | $6.31 | $63K | 53,587 |
| 2025-04-30 | Andrade Robert CHIEF FINANCIAL OFFICER | Grant or award | +1,042 | 133,633 | ||
| 2025-04-30 | Raykov Rosty Director | Grant or award | +2,431 | 63,587 | ||
| 2025-04-11 | RALLIS CHRIS A Director | Option exercise 10b5-1 | +2,173 | $2.30 | $5K | 55,193 |
| 2025-04-11 | RALLIS CHRIS A Director | Sale 10b5-1 | −1,409 | $4.95 | $7K | 53,784 |
| 2025-04-11 | RALLIS CHRIS A Director | Option exercise · Common Shares 10b5-1 | −2,173 | $2.30 | $5K | 180,533 |
| 2025-04-04 | Raykov Rosty Director | Sale 10b5-1 | −10,000 | $5.25 | $53K | 61,156 |
| 2025-03-31 | Raykov Rosty Director | Grant or award | +2,431 | 71,156 |
Page 9 of 17 · 340 trades